Belimumab for early lupus activity in the first two years
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lupus (SLE) and it was diagnosed within the last 2 years
- Your blood tests show ANA positive and anti–double-stranded DNA (anti-dsDNA) positive
- Your lupus activity is mild to moderate (SLEDAI-2K score of 4 or higher)
- Your steroid dose is stable and not too high (30 mg per day or less) for the past 4 weeks
- You take hydroxychloroquine unless you cannot tolerate it
- If you could become pregnant, you must have a negative pregnancy test and use birth control during treatment and for 16 weeks after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is building a national biobank (a storage of blood and health information) to learn more about lupus in people who were recently diagnosed (within the last 2 years). It's for patients whose lupus is not causing serious damage to major organs, so that researchers can study how the disease behaves early on.
This Phase 2 trial tests sirolimus (a medicine that affects the immune system) to reduce symptoms and disease activity in adults with active systemic lupus erythematosus (SLE). You may be a good fit if your lupus is currently active despite stable standard treatments.
This Phase 2 study tests whether combining belimumab and rituximab can improve skin thickening in people with early diffuse cutaneous systemic sclerosis (dcSSc). It may help slow the disease process and improve skin symptoms, but it also requires screening for immune and infection risks.
This study tests whether a medicine called belimumab (Benlysta) works better for people diagnosed with lupus in the last 2 years. It aims to slow down the disease before it causes lasting organ damage.
This study looks at people with systemic lupus (lupus) who have already started belimumab (a lupus medicine). It mainly focuses on whether participants who meet lupus diagnosis rules and choose to join can be followed in the study.
This study compares two medications, Telitacicept and Belimumab, to see which works better for people with active lupus that hasn't improved with standard treatments. The goal is to find a more effective option for managing symptoms.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.